Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: A population-based comparison

Journal of the American College of Cardiology

Volumn 27, Issue 6, 1996, Pages 1335-1342

  Jha, P ^a,b   Deboer, Don ^a   Sykora, Kathy ^a   Naylor, C David ^a,c,d  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b WORLD BANK   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

EID: 0029878321     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00018-6     Document Type: Article

References (41)

1. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
2. FTT Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
3. Naylor CD, Chen E. Population-wide mortality trends among patients hospitalized for acute myocardial infarction: the Ontario experience, 1981-1991. J Am Coll Cardiol 1994;24:1431-8.
4. Goldberg RJ, Gorak EJ, Yarzebski J, et al. A community-wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease. Circulation 1993;87:1947-53.
5. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. LATE Investigators. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
7. Statistics Canada, Health Division, Nosology Reference Centre. Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures. Ottawa: Author, 1986.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83.
9. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-9.
10. Chen E, Naylor CD. Variation in hospital length of stay for acute myocardial infarction in Ontario, Canada. Med Care 1994;32:420-35.
11. Automatch, version 2.7. Silver Spring, MD: Matchware Technologies Inc., 1993.
12. Walraven CV, Wang B, Ugnat AM, Naylor CD. False-positive coding for acute myocardial infarction on hospital discharge records: Chart audit results from a tertiary centre. Can J Cardiol 1990;6:383-6.
13. Iezzoni LI, Burnside S, Sickles L, et al. Coding of acute myocardial infarction and policy implications. Ann Intern Med 1988;109:745-51.
14. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarction treated with thrombolysis. The investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). N Engl J Med 1993;329:1442-8.
15. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91: 1659-68.
16. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-9.
17. Breslow NE, Day NE. Statistical Methods in Cancer Research: Volume 1: The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer, 1980:192-247.
18. GISSI-2. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction; Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990;336:65-71.
19. Hannaford PC, Kay CR, Ferry S. Agism as explanation for sexism in provision of thrombolysis. Br Med J 1994;309:573.
20. Cox J, Chen E, Naylor CD. Revascularization after acute myocardial infarction: Impact of hospital teaching status and on-site invasive facilities. J Gen Intern Med 1994;9:674-8.
21. Jaglal SB, Goel V, Naylor CD. Sex differences in the use of invasive coronary procedures in Ontario. Can J Cardiol 1994;10:239-44.
22. Naylor CD, Jaglal SB. Impact of intravenous thrombolysis on short-term coronary revascularization rates: a meta-analysis. JAMA 1990;264:697-702.
23. Verstraete M, Bleifeld W, Brower RW, et al. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985;2:965-9.
24. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase 1 findings. N Engl J Med 1985;312:932-6.
25. Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985;1:842-7.
26. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-5.
27. ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). N Engl J Med 1986;314:1465-71.
28. ISIS-3 Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. antistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Third International Study of Infarct Survival. Lancet 1992;339: 753-70.
29. Fleming C, D'Agostino RB, Selker HP. Is coronary-care-unit admission restricted for elderly patients? A multicenter study. Am J Public Health. 1991;81:1121-6.
30. Pagley PR, Yarzebski J, Goldberg R, et al. Gender differences in · the treatment of patients with acute myocardial infarction. A multi-hospital, community-based perspective. Arch Intern Med 1993;153:625-9.
31. Montague TJ, Ikuta RM, Wong RY, Bay KS, Teo KK, Davies NJ. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989). Am J Cardiol 1991;68:843-7.
32. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
33. ISIS-4 Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate among 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival. Lancet, 1995;345:669-85.
34. Thompson PL, Parsons RW, Jamrozik K, Hockey RL, Hobbs MS, Broadhurst RJ. Changing patterns of medical treatment in acute myocardial infarction. Observations from the Perth MONICA Project 1984-1990. Med J Aust 1992;157:87-92.
35. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 1993;11(suppl 4):S61-73.
36. Cleary PD, Greenfield S, Mulley AG, et al. Variations in the length of stay and outcomes for six medical and surgical diagnoses in Massachusetts and California. JAMA 1991;266:73-9.
37. Health Services Research Group. Quality of care: what is "quality" and how can it be measured? Can Med Assoc J 1992;146:2153-60.
38. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-9.
39. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991;18:657-62.
40. Naylor CD. Health policy implications of thrombolytic therapy for acute myocardial infarction. In: Califf RM, Wagner G, Mark DB, eds. Coronary Care in the Thrombolytic Era. St. Louis: Mosby Yearbook, 1994:923-37.
41. Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991;266:528-32.